- Home
- PFLT vs TNGX Comparison
PFLT vs TNGX Comparison
Compare PFLT & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFLT
- TNGX
- Stock Information
- Founded
- PFLT 2010
- TNGX 2014
- Country
- PFLT United States
- TNGX United States
- Employees
- PFLT N/A
- TNGX N/A
- Industry
- PFLT Finance: Consumer Services
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- PFLT Finance
- TNGX Health Care
- Exchange
- PFLT Nasdaq
- TNGX Nasdaq
- Market Cap
- PFLT 1.0B
- TNGX 351.2M
- IPO Year
- PFLT N/A
- TNGX N/A
- Fundamental
- Price
- PFLT $10.34
- TNGX $5.02
- Analyst Decision
- PFLT Buy
- TNGX Strong Buy
- Analyst Count
- PFLT 6
- TNGX 6
- Target Price
- PFLT $11.17
- TNGX $12.20
- AVG Volume (30 Days)
- PFLT 821.9K
- TNGX 4.0M
- Earning Date
- PFLT 08-06-2025
- TNGX 08-06-2025
- Dividend Yield
- PFLT 11.90%
- TNGX N/A
- EPS Growth
- PFLT N/A
- TNGX N/A
- EPS
- PFLT 0.86
- TNGX N/A
- Revenue
- PFLT $232,975,000.00
- TNGX $40,990,000.00
- Revenue This Year
- PFLT $45.52
- TNGX N/A
- Revenue Next Year
- PFLT $8.87
- TNGX N/A
- P/E Ratio
- PFLT $11.99
- TNGX N/A
- Revenue Growth
- PFLT 49.56
- TNGX 10.09
- 52 Week Low
- PFLT $8.82
- TNGX $1.03
- 52 Week High
- PFLT $12.02
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- PFLT 49.68
- TNGX 69.44
- Support Level
- PFLT $10.02
- TNGX $4.70
- Resistance Level
- PFLT $10.43
- TNGX $5.63
- Average True Range (ATR)
- PFLT 0.16
- TNGX 0.60
- MACD
- PFLT -0.02
- TNGX -0.01
- Stochastic Oscillator
- PFLT 38.79
- TNGX 65.38
About PFLT PennantPark Floating Rate Capital Ltd.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generate revenue in the form of interest income on the debt securities and dividends.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.